Stock Market Impact: Jefferies assigns a Hold rating to Merck KGaA with a €129 price target, indicating limited upside and a neutral stance for investors.
Listed Companies and Sectors: The coverage focuses on Merck KGaA, highlighting its Life Science division as the primary growth engine, with additional exposure to semiconductor materials (Electronics) and rare‑disease portfolio (Healthcare).
Investment Flows: No specific measures affecting FDI/FPI are mentioned; the analysis is confined to equity valuation and growth expectations.
Interest Rates, Inflation, and Liquidity: The article does not discuss monetary policy, interest rates, inflation, or liquidity conditions.
Fiscal or Monetary Policy: No fiscal or monetary policy actions are referenced.
Growth Outlook: Jefferies forecasts group revenue growth of 4.7% per year from 2025 to 2029, aligning with Merck’s medium‑term guidance, and expects adjusted EBITDA margins to improve to about 30% over the same period, driven mainly by operational leverage in Life Sciences.
Segment Expectations: Electronics is projected to deliver mid‑ to high‑single‑digit growth, supported by AI‑driven demand for advanced semiconductor materials; Healthcare is expected to return to modest growth, aided by recent rare‑disease product launches, though some mature healthcare businesses may continue to decline.
Valuation Commentary: The current share price already reflects most of the structural growth opportunities; meaningful upside would require stronger execution in Life Sciences, faster rare‑disease growth, or a more durable semiconductor cycle.
Risk‑Reward Profile: Jefferies describes a balanced risk‑reward profile, awaiting greater visibility on future catalysts before adopting a more constructive view.
